FORX-428 for Solid Tumors

This trial tests a new drug, FORX-428, to assess its safety and tolerability at different doses. It focuses on individuals with advanced solid tumors that have genetic changes, such as BRCA1/2 mutations, which can increase cancer risk. The goal is to identify the highest dose that people can tolerate without excessive side effects. Suitable candidates have advanced breast or ovarian cancer that has progressed despite previous treatment and possess specific genetic markers in their tumors. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new drug.

The trial does not specify if you need to stop taking your current medications, but you must not have received any anti-cancer treatment or investigational agent within 14 days before starting the trial. It's best to discuss your current medications with the trial team.

Research has shown that FORX-428 was safe in lab studies, which tested the treatment on various solid tumors. The results were promising, indicating that FORX-428 was well-tolerated and effective against tumors. However, this trial marks the first time FORX-428 is being tested in humans. Researchers are closely monitoring patient responses to different doses to ensure safety. As this is an early-phase study, the primary goal is to determine a safe dose and identify any side effects.¹²³⁴⁵

Unlike the standard treatments for solid tumors, which often involve chemotherapy or radiation, FORX-428 stands out due to its novel mechanism of action. It specifically targets cancer cells with a unique pathway, potentially reducing harm to healthy cells and minimizing side effects. Researchers are excited about FORX-428 because it offers a more targeted approach, which could lead to improved outcomes and better quality of life for patients. Additionally, the ability to adjust doses in this study may help find the most effective and safe regimen for patients with different tumor types.

Research shows that FORX-428, the investigational drug in this trial, could effectively treat solid tumors. Early studies have found that this drug targets pathways that repair damaged DNA in cancer cells, making it potentially useful for tumors with BRCA1/2 mutations or other DNA repair issues. Initial data suggest that FORX-428 is likely safe and may not cause many side effects. Although human studies provide limited information, these results are promising for its potential use in advanced solid tumors. Participants in this trial will receive FORX-428 as part of a dose escalation/expansion cohort study to further evaluate its safety and effectiveness.¹²⁵⁶⁷